Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.

Date publication

janvier 2016

Journal

RMD open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27252898

Résumé

Use of prediction matrices of risk or rapid radiographic progression (RRP) for early rheumatoid arthritis (RA) in clinical practice could help to better rationalise the first line of treatment. Before use, they must be validated in populations that have not participated in their construction. The main objective is to use the ESPOIR cohort to validate the performance of 3 matrices (ASPIRE, BEST and SONORA) to predict patients at high risk of RRP at 1 year of disease despite initial treatment with methotrexate (MTX).

Mots clés

Early Rheumatoid Arthritis, Epidemiology, Rheumatoid Arthritis, Treatment

Référence

RMD Open. 2016 ;2(1):e000245